Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use Biodexa plans ...

Almirall as European leader in Medical Dermatology: we delivered impactful products to more patients and the medical community. Our double-digit sales growth and increased profitability demonstrate ...

A gene called high mobility group A1 (HMGA1) may be the key that opens the door to the development of colon cancer, according ...

A gene called high mobility group A1 (HMGA1) may be the key that opens the door to the development of colon cancer, according ...

If a person has a type of noncancerous polyp called an adenomatous polyp, they have an increased risk of developing colon cancer. These polyps form on the inner walls of the large intestine.

The safety of three therapeutic methods, each featuring electromagnetic navigation bronchoscopy-guided microwave ablation, was established in patients with multiple bilateral ground-glass opacities, ...

Recursion Pharmaceuticals RXRX is expected to report its fourth-quarter 2024 results soon. The Zacks Consensus Estimate for ...

A gene called high mobility group A1 (HMGA1) may be the key that opens the door to the development of colon cancer, according to research led by investigators from the Johns Hopkins Kimmel Cancer ...

Sapience Therapeutics, Inc. 是一家临床阶段生物技术公司，专注于发现和开发肽疗法以解决导致癌症的致癌和免疫失调，该公司宣布，美国食品和药物管理局 (FDA) 已授予 ST316 孤儿药资格 (ODD)，用于治疗家族性腺瘤性息肉病 (FAP)。

Recursion Pharmaceuticals RXRX is expected to report its fourth-quarter 2024 results soon. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is pegged at $28.73 ...